About ACER

Opexa is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases such as neuromyelitis optica (NMO). These therapies are based on Opexa's proprietary T-cell technology. The Company's leading therapy candidate, Tcelna(R), is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of secondary progressive MS. Tcelna consists of myelin-reactive T-cells, which are expanded ex vivo from the patient's peripheral blood and reintroduced into the patient in an attenuated form via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin for each individual patient.
Primary Exchange: NASDAQ
SIC Pharmaceutical Preparations
NAICS Pharmaceutical Preparation Manufacturing

ACER is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
URTY ProShares UltraPro Russell2000 81.1 M 8.1125E+07 2,012 2012 0.0% 1.57316E-06 396 396
UWM ProShares Ultra Russell2000 149.7 M 1.49742E+08 2,011 2011 0.0% 2.26253E-06 728 728
VTI Vanguard Total Stock Market ETF 119.5 B 1.195E+11 3,575 3575 0.0% 0 34 K 33664
VTWG Vanguard Russell 2000 Growth ETF 307.1 M 3.071E+08 1,329 1329 0.0% 1E-05 5 K 4504
VTWO Vanguard Russell 2000 ETF 1.5 B 1.5E+09 2,029 2029 0.0% 1E-05 11 K 11328
VXF Vanguard Extended Market ETF 7.3 B 7.3E+09 3,266 3266 0.0% 0 21 K 21122
ITOT iShares Core S&P Total U.S. Stock Market ETF 22.0 B 2.20343E+10 3,546 3546 0.0% 0 802 802
IWC iShares Microcap ETF 800.2 M 8.00224E+08 1,388 1388 0.0% 0 34 K 34056
IWM iShares Russell 2000 ETF 41.0 B 4.10203E+10 2,000 2000 0.0% 0 232 K 232399
IWO iShares Russell 2000 Growth ETF 9.0 B 9.04593E+09 1,146 1146 0.0% 0 100 K 99722